The hypoxic cell sensitizer programme in the United States.
The initial results of a Phase I evaluation of misonidazole in the U.S.A. are described, as well as the U.S. National Cancer Institute programme for radiosensitizer development. A total of 12 patients have been given 1--6 doses of 1--2 g/m2. Serum levels ranged from 25--87 microgram/ml at 4--6 h. One patient has developed mild peripheral neuropathy. Urinary excretion was chiefly of a demethylated metabolite as measured by HPLC assay.
D000368:Aged; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000532:radiotherapy; D009593:Nitroimidazoles / Q000378:metabolism* / Q000633:toxicity; D011838:Radiation-Sensitizing Agents; D014481:United States
D009593:Nitroimidazoles; D011838:Radiation-Sensitizing Agents